KRIYA Institute is proud to be partnered with Valis Bioscience in the Open Ketamine Project (formerly known as the Bodhisattva Ketamine Project). The purpose of this project is to earn FDA approval for generic (racemic) ketamine for a mental health application.
This project will demonstrate (confirm) the safety and efficacy of generic ketamine as a treatment for humans who are experiencing depression that has not responded adequately to other treatments. FDA approval is essential for unlocking medical insurance coverage for ketamine-assisted psychotherapy (KAP) services. It will also enable large healthcare systems to utilize generic ketamine for mental health treatment. This approval is important for legitimizing the use of generic ketamine in clinical practice, and will provide protection to practitioners who choose to work with this tool.
Updated on 10/22/24